R&D Can genetic data be a magic bullet for drug R&D? Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments.
Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.